Recommended guidelines for the management of autologous and allogeneic bone marrow transplantation: A report from the Eastern Cooperative Oncology Group (ECOG)

Annals of Internal Medicine

Volumn 120, Issue 2, 1994, Pages 143-158

  Rowe, Jacob M ^a,f   Ciobanu, Niculae ^a,d   Ascensao, Joao ^a,c   Stadtmauer, Edward A ^a,h   Weiner, Roy S ^a,i   Schenkein, David P ^a,g   McGlave, Philip ^a,e   Lazarus, Hillard M ^a,b  

^a Eastern Cooperative Oncology Group   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c UNIVERSITY OF NEVADA   (United States)

^d ST VINCENT S HOSPITAL   (United States)

^e UNIV OF MINNESOTA HOSP AND CLINIC   (United States)

^f UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^g TUFTS MEDICAL CENTER   (United States)

^h HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ TULANE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOPOIETIC GROWTH FACTOR;

ACUTE LYMPHOCYTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; APLASTIC ANEMIA; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; COMPUTER ASSISTED DIAGNOSIS; CYTOMEGALOVIRUS INFECTION; DATA ANALYSIS; GRAFT VERSUS HOST REACTION; MEDICAL CARE; PRIORITY JOURNAL; REVIEW; VEIN OCCLUSION;

EID: 0028157637     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-120-2-199401150-00008     Document Type: Review

References (200)

1. Thomas ED. Karnofsky Memorial Lecture: marrow transplantation for malignant diseases. J Clin Oncol. 1983;1:517-31.
2. O'Reilly RJ. Allogeneic bone marrow transplantation: current status and future directions. Blood. 1983;62:941-64.
3. Appelbaum FR, Fisher LD, Thomas ED. Chemotherapy vs marrow transplantation for adults with acute nonlymphocytic leukemia: a five-year follow-up. Blood. 1988;72:179-84.
4. Blume KG, Forman SJ, Snyder DS, Nademanee AP, O'Donnell MR, Fahey JL, et al. Allogeneic bone marrow transplantation for acute lymphoblastic leukemia during first complete remission. Transplantation. 1987;43:389-92.
5. Gahrton G, Tura S, Ljungman P, Belanger C, Brandt L, Cavo M, et al. Allogeneic bone marrow transplantation in multiple myeloma. N Engl J Med. 1991;325:1267-73.
6. Applebaum FR, Barrall J, Storb R, Fisher LD, Schoch G, Ramberg RE, et al. Bone marrow transplantation for patients with myelodysplastic syndromes: pretreatment variables and outcome. Ann Intern Med. 1990;112:590-7.
7. Kernan NA, Bartsch G, Ash RC, Beatly PG, Champlin R, Filipovich A, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med. 1993;328:593-602.
8. Cheson BD, Lacerna L, Leyland-Jones B, Sarosy G, Wittes RE. Review. Autologous bone marrow transplantation. Current status and future directions. Ann Intern Med. 1989;110:51-65.
9. Cassileth PA, Andersen J, Lazarus HM, Colvin OM, Bennett JM, Stadtmauer EA, et al. Autologous bone marrow transplant in acute myeloid leukemia in first remission. J Clin Oncol. 1993;11:314-9.
10. Lazarus HM, Crilley P, Ciobanu N, Creger RJ, Fox RM, Shina DC, et al. High-dose carmustine, etoposide, cisplatin (BEP) and autologous bone marrow transplantation for relapsed and refractory lymphoma. J Clin Oncol. 1992;10:1682-9.
11. Philip T, Armitage JO, Spitzer G, Chauvin F, Jagannath S, Cahn JY, et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med. 1987;316:1493-8.
12. Barloggie B, Gahrton G. Bone marrow transplantation in multiple myeloma. Bone Marrow Transplant. 1991;7:71-9.
13. Antman K, Ayash L, Elias A, Wheeler C, Hunt M, Eder JP, et al. A phase II study of high dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measureable advanced breast cancer responding to standard-dose therapy. J Clin Oncol. 1992;10:102-10.
14. Kennedy MJ, Beveridge RA, Rowley SD, Gordon GB, Abeloff MD, Davidson NE. High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer. J Natl Cancer Inst. 1991;83: 920-6.
15. Nichols CR, Andersen J, Lazarus HM, Fisher H, Greer J, Stadtmauer EA, et al. High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Cooperative Oncology Group Protocol. J Clin Oncol. 1992;10:1-6.
16. Frei E 3d, Antman K, Teicher B, Eder P, Schnipper L. Bone marrow autotransplantation for solid tumors-prospects. J Clin Oncol. 1989;7:515-26.
17. The American Society of Clinical Oncology and American Society of Hematology. Recommended criteria for the performance of bone marrow transplantation: Special Report. J Clin Oncol. 1990;8: 563-4.
18. Transplant Center Participation Criteria: Report of the National Marrow Donor Program; March 1991. [National Marrow Donor Program, 3433 Broadway Street, N.E., Suite 400, Minneapolis, MN 55413.]
19. McCullough J, Hansen J, Perkins H, Stroncek D, Bartsch G. The National Marrow Donor Program: how it works, accomplishments to date. Oncology. 1989;3:63-6.
20. Anasetti C, Amos D, Beatty PG, Appelbaum FR, Bensinger W, Buckner CD, et al. Effect of HLA-compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med. 1989;320:197-204.
21. Anasetti C, Beatty PG, Storb R, Martin PJ, Mori M, Sanders JE, et al. Effect of HLA-incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol. 1990;29:79-91.
22. Beatty PG, Hansen JA, Lonoton GM, Thomas ED, Sanders JE, Martin PJ, et al. Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. Transplantation. 1991;5:443-7.
23. Beatty PG, Clift RA, Mickelson EM, Nisperos BB, Flournoy N, Martin PJ, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med. 1985;313:765-71.
24. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host reaction (GvHR) in human recipients of marrow from HLA-matched sibling donors. Transplantation. 1974;18:295-304.
25. Thomas ED, Storb R, Clift RA, Fefer A, Johnson L, Neiman PE, et al. Bone-marrow transplantation. N Engl J Med. 1975;292:895-902.
26. Atkinson K, Horowitz MM, Biggs JC, Gale RP, Rimm AA, Bortin MM. The clinical diagnosis of acute graft-versus-host disease: A diversity of views amongst marrow transplant centers. Bone Marrow Transplant. 1988;3:5-10.
27. Atkinson K, Horowitz MM, Gale RP, van Bekkum DW, Gluckman E, Good RA, et al. Risk factors for chronic graft versus host disease after HLA-identical sibling bone marrow transplantation. Blood. 1990;75:2459-64.
28. Lerner KG, Kao GF, Storb R, Buckner CD, Clift RA, Thomas ED. Histopathology of graft-vs-host reaction (GvHR) in human recipients of marrow from HLA-matched sibling donors. Trans Proc. 1974;6:367-71.
29. Sullivan KM, Witherspoon RP, Storb R, Anasetti C, Appelbaum FR, Bigelow C, et al. Chronic graft-versus-host disease: recent advances in diagnosis and treatment. In: Gale RP, Champlin RE; eds. Current Controversies. New York: Alan R. Liss, Inc.; 1989; 511-22..
30. Woodruff JM, Hansen JA, Good RA, Santos GW, Slavin RE. The pathology of the graft-versus-host reaction (GVHR) in adults receiving bone marrow transplants. Trans Proc. 1976;8:675-84.
31. Sale GE, Lerner KG, Barker EA, Shulman HM, Thomas ED. The skin biopsy in the diagnosis of acute graft-versus-host disease in man. Am J Pathol. 1977;89:621-35.
32. Vogelsang GB, Hess AD, Santos GW. Acute graft-vs-host disease: clinical characteristics in the cyclosporine era. Medicine (Baltimore). 1988;67:163-74.
33. Graw RG Jr, Santos GW. Bone marrow transplantation in patients with leukemia. Incidence and severity of graft-vs-host disease and successful HLA-matched transplants. Transplantation. 1971;11: 197-9.
34. Hershko C, Gale RP. GVHD scoring system for predicting survival and specific mortality in bone marrow transplant recipients. In: Gale RP; ed. Biology of Bone Marrow Transplantation. New York: Academic Press; 1980:159-69.
35. Vogelsang GB. Acute graft-vs-host disease. In: Champlin R; ed. Bone Marrow Transplantation. Boston: Kluwer Academic Publishers; 1990:55-67.
36. Shuman HM, Sullivan KM, Weiden PL, McDonald G, Striker G, Sale G, et al. Chronic graft-versus-host syndrome in man. A long-term clinical pathological study of 20 Seattle patients. Am J Med. 1980;69:204-17.
37. Atkinson K, Horowitz M, Gale RP, Lee MB, Rimm AA, Bortin MM. Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease. Bone Marrow Transplant. 1989;4;247-54.
38. Sullivan KM. Graft-versus-host disease. In: Blume KG, Petz LD; eds. Clinical Bone Marrow Transplantation. New York: Churchill-Livingslone; 1983;91-129.
39. Gale RP, Armitage JO, Dicke KA. Autotransplants: now and in the future. Bone Marrow Transplant. 1991;7:153-7.
40. Butturini A, Bortin MM, Gale RP. Graft-versus-leukemia following bone marrow transplantation. Bone Marrow Transplant. 1987;2: 233-42.
41. Jones RJ, Ambinder RF, Piantadosi S, Santos GW. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood. 1991;77:649-53.
42. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555-62.
43. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med. 1986; 314:729-35.
44. Santos GE. Allogeneic, syngeneic, and autologous bone marrow transplantation in the acute leukemias-the Baltimore experience. Clin Trans. 1987;1:21-8.
45. Forman SJ, O'Donnell MR, Nademanee AP, Snyder DS, Bierman PJ, Schmidt GM, et al. Bone marrow transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 1987;70:587-8.
46. Yee GC, Self SG, McGuire TR, Carlin J, Sanders JE, Deeg HJ. Serum cyclosporine concentration and risk of acute graft-versus-host disease after allogeneic marrow transplantation. N Engl J Med. 1988;319:65-70.
47. Yee GC, Kennedy MS, Deeg HJ, Leonard TM, Thomas ED, Storb R. Cyclosporine-associated renal dysfunction in marrow transplant recipients. Trans Proc. 1985;17:196-201.
48. Gratwohl A, Speck B, Wenk M, Forster I, Muller M, Osterwalder B, et al. Cyclosporine in human bone marrow transplantation. Serum concentration, graft-versus-host disease, and nephrotoxicity. Transplantation. 1983;26:40-4.
49. Deeg HJ, Loughran TP Jr, Storb R, Kennedy MS, Sullivan KM, Doney K, et al. Treatment of human acute graft-versus-host disease with antithymocyte globulin and cyclosporine with or without methylprednisolone. Transplantation. 1985;40:162-6.
50. Lindholm A, Ringden O, Lonnquist B. The role of cyclosporine dosage and plasma levels in efficacy and toxicity in bone marrow transplant recipients. Transplantation. 1987;43:680-4.
51. Holler E, Kolb HJ, Hiller E, Mraz W, Lechmacker W, Gleixner B, et al. Microangiopathy in patients on cyclosporine prophylaxis who developed acute graft-versus-host disease after HLA-identical bone marrow transplantation. Blood. 1989;73:2018-24.
52. Juckett M, Terry EH, Daniels BS, Weisdorf DJ. Hemolytic uremic syndrome following bone marrow transplantation. Bone Marrow Transplant. 1991;7:405-9.
53. Donatsch P, Ablsch E, Homberger M, Traber R, Trapp M, Voges R. A radioimmunoassay to measure cyclosporin A in plasma and serum sample. J Immunoassay. 1981;2:19-32.
54. Fay JW, Weisdorf DJ, Wingard JR, Antln JH, Collins RH, Blazar BR, et al. FK506 monotherapy for prevention of graft versus host disease after histocompatible sibling marrow transplantation [Abstract]. Blood. 1992;80:531A.
55. Martin PJ, Schoch G, Fisher L, Byers V, Anasetti C, Appelbaum F, et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood. 1990;76:1464-72.
56. Weisdorf D, Haake R, Blazar B, Miller W, McGlave P, Ramsay N, et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood. 1990;75:1024-30.
57. Kennedy MS, Deeg HJ, Storb R, Doney K, Sullivan KM, Witherspoon RP, et al. Treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Randomized study comparing corticosteriods and cyclosporine. Am J Med. 1985;78:978-83.
58. Byers VS, Henslee PJ, Kernan NA, Blazar BR, Gingrich R, Phillips GL, et al. Use of anti-pan T-lymphocyte ricin a chain immunotoxin in steroid-resistant acute graft-versus-host disease. Blood. 1990;75: 1426-32.
59. Doney KC, Weiden PL, Storb R, Thomas ED. Treatment of graft-versus-host disease in human allogeneic marrow graft recipients: a randomized trial comparing antithymocyte globulin and corticosteriods. Am J Hematol. 1981;11:1-8.
60. Sullivan KM, Witherspoon RP, Storb R, Weiden P, Flournoy N, Dahlberg S, et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia and allogeneic bone marrow transplant. Blood. 1988;72:546-54.
61. Martin PJ, Schoch G, Fisher L, Byers V, Appelbaum FR, McDonald GB, et al. A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood. 1991;77:1821-8.
62. Jampel RM, Farmer ER, Vogelsang GB, Wingard J, Santos GW, Morison WL. PUVA therapy for chronic cutaneous graft-vs-host disease. Arch Dermatol. 1991;127:1673-88.
63. Vogelsang GB, Farmer ER, Hess AB, Altamonte V, Beschorner WE, Jabs DA, et al. Thalidomide therapy of chronic graft-versus-host disease. N Engl J Med. 1992;326:1055-8.
64. Markus PM, Cai X, Ming W, Demetris AJ, Fung JJ, Starzl TE. FK506 reverses acute graft-versus-host disease after allogeneic bone marrow transplantation in rats. Surgery. 1991;110:357-63.
65. Tiberghien P, Racadot E, Lioure B, Delain M, Girard A, Wijdenes J, et al. Soluble CD8, IL-2 receptor, and tumor necrosis factor-alpha levels in steroid-resistant acute graft-versus-host disease. Relation with subsequent response to anti-IL-2 receptor monoclonal antibody treatment. Transplantation. 1991;52:475-80.
66. McCarthy PL, Abhyankar S, Neben S, Newman G, Seiff C, Thompson RC, et al. Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease. Blood. 1991;78: 1915-8.
67. Leoung GS, Feigal OW Jr, Montgomery AB, Corkery K, Wardlaw L, Adams M, et al. Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia. The San Francisco Community Prophylaxis Trial. N Engl J Med. 1990;323:769-75.
68. Centers for Disease Control. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons with human immunodeficiency virus. JAMA. 1989;262:335-38.
69. Mills J, Leoung G, Medina I, Hopewell PC, Hughes WT, Wofsy C. Dapsone treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Antimicrob Agents Chemother. 1988;32:1057-60.
70. Powderly WG, Kobayshi GS, Herzig GP, Medoff G. Amphotericin B-resistant yeast infection in severely immunocompromised patients. Am J Med. 1988;84:826-32.
71. Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 1992;326:845-51.
72. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida kruseii infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med. 1991;325:1274-47.
73. Tam JY, Blume KE, Prober CT. Prophylactic fluconazole and Candida kruseii infections. N Engl J Med. 1992;326:891-2.
74. Rousey SR, Russler S, Gottleib M, Ash RC. Low-dose amphotericin B prophylaxis against invasive Aspergillus infections in allogeneic marrow transplantation. Am J Med. 1991;91:484-92.
75. Perfect JR, Klotman ME, Gilbert CC, Crawford DD, Rosner GL, Wright KA, et al. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis. 1992;165:891-7.
76. Burch PA, Karp JE, Merz WG, Kuhlman JE, Fishman EK. Favorable outcome of invasive aspergillosis in patients with acute leukemia. J Clin Oncol. 1987;5:1985-93.
77. Nemunaitis J, Meyers JD, Buckner CD, Shannon-Dorcy K, Mori M, Shulman H, et al. Phase 1 trial of recombinant human macrophage colony-stimulating factor in patients with invasive fungal infections. Blood. 1991;78:907-13.
78. Lopez-Berestein G, Bodey GP, Fainstein V, Keating M, Frankel LS, Zeluff B, et al. Treatment of systemic fungal infections with liposomal amphotericin B. Arch Intern Med. 1989;149:2533-6.
79. Chopra R, Blair S, Strang J, Cervi P, Patterson KG, Goldstone AH. Liposomal amphotericin B (AmBisome) in the treatment of fungal infections in neutropenic patients. J Antimicrob Chemoth. 1991;28: 93-104.
80. Ringden O, Meunier F, Tollemar J, Ricci P, Tura S, Kuse E, et al. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemoth. 1991;28:73-82.
81. Meyers JD. Infections in recipients of marrow transplantation. In: Swartz MN, Remington JS; eds. Current Clinical Topics in Infectious Diseases. New York: McGraw-Hill; 1985:261-92.
82. Pecego R, Hill R, Appelbaum FR, Amos D, Buckner CD, Fefer A, et al. Interstitial pneumonitis following autologous bone marrow transplantation. Transplantation. 1986;42:515-7.
83. Wingard JR, Chen DY, Burns WH, Fuller DJ, Braine HG, Yeager AM, et al. Cytomegalovirus infection after autologous bone marrow transplantation with comparison to infection after allogeneic bone marrow transplantation. Blood. 1992;71:1432-7.
84. Bowden RA, Sayers M, Flournoy N, Newton B, Banaji M, Thomas ED, et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med. 1986;314:1006-10.
85. Miller WJ, McCullough J, Balfour HH Jr, Haake RJ, Ramsay NK, Goldman A, et al. Prevention of cytomegalovirus infection following bone marrow transplantation: a randomized trial of blood product screening. Bone Marrow Transplant. 1991;7:227-34.
86. Elfenbein G, Krischer K, Graham-Pole J, Hong R, Jansen J, Lazarus H. Intravenous immunoglobulins for cytomegalovirus pneumoni. In: Imbach P; ed. Immunotherapy with Intravenous Immunoglobulin. London: Academic Press Ltd.; 1991:219-29.
87. Sullivan KM, Kopecky KJ, Jocom J, Fisher L, Buckner CD, Meyers JD, et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med. 1990;323:705-12.
88. Verdonck LF, de Graan-Hentzen YC, Dekker AW, Mudde GC, de Gast GC. Cytomegalovirus seronegative platelets and leukocytepoor red blood cells from random donors can prevent primary cytomegalovirus infection after bone marrow transplantation. Bone Marrow Transplant. 1987;2:73-8.
89. de Graan-Hentzen YCE, Gratama JW, Mudde GC, Verdonck LF, Houbierts JG, Brand A, et al. Prevention of primary cytomegalovirus infection in patients with hematologic malignancies by intensive white cell depletion of blood products. Transfusion. 1989;29: 757-60.
90. Bowden RA, Slichter SJ, Sayers MH, Mori M, Cays MJ, Meyers JD. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood. 1991;78:246-50.
91. De Witte T, Schattenberg A, Van Dijk BA, Galama J, Olthuis H, Van der Meer JM, et al. Prevention of primary cytomegalovirus infection after allogeneic bone marrow transplantation by using leukocyte-poor random donor blood products from cytomegalovirus-unscreened blood-bank donors. Transplantation. 1990;50:964-8.
92. Schiffer C. Prevention of alloimmunization against platelets. Blood. 1991;77:124-6.
93. Nemo GJ, McCurdy PR. Prevention of platelet alloimmunization. Transfusion. 1991;31:584-86.
94. Reed EC, Bowden RN, Dandliker PS, Lilleby KE, Meyers JD. Treatment of cytomegalovirus pneumorria with ganciclovir and intravenous cytomegalovirus immunoglobin in patients bone marrow transplants. Ann Intern Med. 1988;109:783-88.
95. Emanuel D, Cunningham I, Jules-Elysee K, Brochsteln JA, Kernan NA, Laver J, et al. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with a combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med. 1988;109:777-82.
96. Reed E, Bowden R, Dandliker P, Lilleby PS, Meyers JD. Treatment of cytomegalovirus pneumonia in marrow transplant patients with ganciclovir and intravenous cytomegalovirus immunoglobulin. In: Dicke KA, Spitzer G, Jagannath S, eds. Autologous Bone Marrow Transplantation: Proc. 4th Intl Symposium Houston, University of Texas, MD Andersen Hospital. 1989:743-46.
97. Schmidt GM, Horak DA, Niiand JC, Duncan SR, Formen SJ, Zaia JA. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants: The City of Hope-Stanford-Syntex CMV Study Group. N Engl J Med. 1991;324:1005-1011.
98. Goodrich JM, Motomi M, Gleaves CA, Du Mond C, Cays M, Ebeling DF, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med. 1991;325:1601-07.
99. Meyers JD, Reed EC, Shepp DH, Thornquist M, Dandliker PS, Vicary CA, et al. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic bone marrow transplantation. N Engl J Med. 1988;318:70-75.
100. Shulman HM, McDonald GB, Matthews D, Doney KC, Kopecky KJ, Gauvreau JM, et al. An analysis of hepatic venoocclusive disease and centrilobular hepatic degeneration following bone marrow transplantation. Gastroenterology. 1980;798:1178-91.
101. Shulman HM, Hinterberger W. Hepatic venoocclusive disease - liver toxicity syndrome after bone marrow transplantation. Bone Marrow Transplant. 1992;10:197-214.
102. McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. The clinical course of 53 patients with venoocclusive disease of the liver after marrow transplantation. Transplantation. 1985;39: 603-8.
103. Dulley FL, Kanfer EJ, Appelbaum FR, Amos D, Hill RS, Buckner CD, et al. Venoocclusive disease of the liver after chemoradiotherapy and autologous bone marrow transplantation. Transplantation. 1987;43:870-73.
104. Jones RJ, Lee KSK, Beschorner WE, Vogel VG, Grochow LD, Braine HG, et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation. 1987;44:778-83.
105. Stromeyer FW, Ishak KG. Nodular transformation (nodular "regenerative" hyperplasia) of the liver: a clinicopathologic study of 30 cases. Hum Pathol. 1981;12:60-71.
106. Snover DC, Weisdorf S, Bloomer J, McGlave P, Weisdorf D. Nodular regenerative hyperplasia of the liver following bone marrow transplantation. Hepatology. 1989;9:443-48.
107. McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. Venoocclusive disease of the liver after bone marrow transplantation: Diagnosis, incidence and predisposing factors. Hepatology. 1984;4:116-22.
108. Bierman SI, Mori M, Hinds MS, McDonald GB. A statistical model to predict unfavorable outcome in patients with venocclusive disease of the liver after marrow transplant. Exp Hematol. 1990;18: 699.
109. McDonald GB, Shulman HM, Wolford JL, Spencer GD. Liver disease after human marrow transplantation. Semin Liver Dis. 1987;7:210-29.
110. McDonald GB, Hinds M, Fisher L, Schoch HG. Liver toxicity following cytoreductive therapy for bone marrow transplantation: risk factors, incidence and outcome. Hepatology. 1991;14:162A.
111. Nevill TJ, Barnett MJ, Klingemann HG, Reece DE, Shephard JD, Phillips GL. Regimen-related toxicity of a busulfan-cyclophosphamide conditioning regimen in 70 patients undergoing allogeneic bone marrow transplantation. J Clin Oncol. 1991;9:1224-32.
112. Bierman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol. 1988;6:1562-6.
113. Ayash LJ, Hunt M, Antman K, Nadler L, Wheeler C, Takvorian T, et al. Hepatic venoocclusive disease in autologous bone marrow transplantation of solid tumors and lymphomas. J Clin Oncol. 1990;8:1699-1706.
114. Gluckman E, Jolivet I, Scrobohaci ML, Deveroi A, Traineau R, Bourdeaux-Esperou H, et al. Use of prostaglandin E1 for prevention of liver venoocclusive disease in leukemic patients treated by allogeneic bone marrow transplantation. Br J Haematol. 1990;74: 277-81.
115. Deeg HJ, Sullivan KM, Buckner CD, Storb R, Appelbaum FR, Clift RA, et al. Marrow transplantation for acute nonlymphoblastic leukemia in first remission: toxicity and long-term follow-up of patients conditioned with single dose or fractionated total body irradiation. Bone Marrow Transplantation. 1986;1:151-7.
116. Cossett JM, Baume D, Pico JL, Shank B, Girinski T, Benhamou E, et al. Single dose versus hyperfractionated total body irradiation before allogeneic bone marrow transplantation: a non-randomized comparative study of 54 patients at the Institut Gustav-Roussy. Radiother Oncol. 1989;15:151-60.
117. Sloane JP, Farthing MJ, Powles RL. Histopathological changes in the liver after allogeneic bone marrow transplantation. J Clin Pathol. 1980;33:344-46.
118. Clift RA, Buckner CD, Appelbaum FR, Bearman SI, Petersen FB, Fisher LD, et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood. 1990;76:1867-71.
119. Radicn J, Sanders J, Buckner CD, Martin P, Petersen FB. Second allogeneic bone marrow transplants for patients relapsing after initial transplant with TBI-containing regimens. Blood. 1991;78: 241A.
120. Morgan M, Dodds A, Atkinson K, Szer J, Downs K, Biggs J. The toxicity of busulfan and cyclophosphamide as the preparative regimen for bone marrow transplantation. Br J Haematol. 1991;77: 529-34.
121. Vassal G, Hartmann O, Benhamou E. Busulfan and venoocclusive disease of the liver. Ann Intern Med. 1990;112:881.
122. Dulley FL, Kanfer EJ, Appelbaum FR, Amos D, Hill RS, Buckner CD, et al. Venoocclusive disease of the liver after chemoradiotherapy and autologous bone marrow transplantation. Transplantation. 1987;43:870-73.
123. Soiffer RJ, Dear K, Rabinowe SN, Anderson KC, Freedman AS, Murray C, et al. Hepatic dynsfunction following T cell depleted allogeneic bone marrow transplantation. Transplantation. 1991;52: 1014-19.
124. Essell JH, Thompson JM, Harman GS, Halvorson RD, Snyder MJ, Johnson RA, et al. Marked increasing venoocclusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan-cyclosphosphamide. Blood. 1992;79:2784-88.
125. Wolford JL, McDonald GB. A problem oriented approach to intestinal and liver disease after marrow transplantation. J Clin Gastroenterol. 1988;10:419-33.
126. Murray JL, LaBrecque DR, Gingrich RD, Pringle KC, Mitros FA. Successful treatment of hepatic venoocclusive disease in a bone marrow transplantation with side-to-side portacaval shunt. Gastroenterology. 1987;92:1073-77.
127. Bearman SI, Shuhart MC, Hinds MS, McDonald GB. A pilot study of recombinant human tissue plasminogen activator (tPA) for the treatment of established severe hepatic venoocclusive disease (VOD) after marrow transplantation [Abstract]. Proc Am Soc Clin Oncol. 1992;11:263A.
128. Baglin TP, Harper P, Marcus RE. Venoocclusive disease of the liver complicating ABMT successfully treated with recombinant tissue plasminogen activator (rt-PA). Bone Marrow Transplant. 1990;5:439-41.
129. Nimer SD, Milewicz AL, Champlin RE, Busuttil RW. Successful treatment of hepatic venoocclusive disease in the bone marrow transplants with orthotopic liver transplantation. Transplantation. 1990;49:819-21.
130. Rhodes DF, Lee WM, Wingard JR, Pavy MD, Santos GW, Shaw BW, et al. Orthotopic transplantation for graft-versus-host disease following bone marrow transplantation. Gastroenterology. 1990;99: 536-8.
131. Rapoport AP, Doyle HR, Starzl T, Rowe JM, Doeblin T, DiPersio JF. Orthotopic liver transplantation for life-threatening venoocclusive disease of the liver after allogeneic bone marrow transplant. Bone Marrow Transplant. 1991;8:421-4.
132. Chan JY, Flesch M, Plouvier E, Herve P, Rozenbaum A. Venoocclusive disease of the liver and autologous bone marrow transplantation: preventive role for heparin? Nouv Rev Fr Hematol. 1985; 27:27-8.
133. Bearman SI, Hinds MS, Wolford JL, Petersen FB, Nugent DL, Slichter SJ, et al. A pilot study of continuous infusion heparin for the prevention of hepatic venoocclusive disease after bone marrow transplantation. Bone Marrow Transplant. 1990;5:407-11.
134. Attal M, Huguet F, Ruble H, Huynh A, Charlet JP, Payen JL, et al. Prevention of hepatic venoocclusive disease after bone marrow transplantation by continuous infusion of low-dose Heparin: a prospective randomized trial. Blood. 1992;79:2834-40.
135. Bearman SI, Hinds MS, McDonald GB. Prostaglandin E1 for the prevention of hepatic venoocclusive disease: results of a phase I study. Exp Hematol. 1991;19:567.
136. Ibrahim A, Pico JL, Maraninchi D, Zambon E, Attal M, Brault P, et al. Hepatic venoocclusive disease following bone marrow transplantation treated by prostaglandin El. Bone Marrow Transplant. 1991;7:53.
137. Nemunaitis J, Rabinowe SN, Singer JW, Bierman PJ, Vose JM, Freedman AS, et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med. 1991;324:1773-8.
138. Taylor KM, Jagannath S, Spitzer G, Spinolo JA, Tucker SL, Fogel B, et al. Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin's disease. J Clin Oncol. 1989;7:1791-9.
139. Gulati CG, Bennett CL. Granulocyte-macrophage colony-stimulating-factor (GM-CSF) as adjunct therapy in relapsed Hodgkin's disease. Ann Intern Med. 1982;116:177-82.
140. Shulman HM, McDonald GB, Matthews D, Doney KC, Kopecky KJ, Gauvreau JM, et al. An analysis of hepatic venoocclusive disease and centrilobular hepatic degeneration following bone marrow transplantation. Gastroenterology. 1980;79:1178-91.
141. Mertelsmann R, Herrmann F, Hecht T, Schulz G. Hematopoietic growth factors in bone marrow transplantation. Bone Marrow Transplant. 1990;6:73-7.
142. Powles R, Smith C, Milan S, Treleaven J, Millar J, McElwain T, et al. Human recombinant GM-CSF in allogeneic bone-marrow transplantation for leukemia: double-blind, placebo-controlled trial. Lancet. 1990;336:1417-20.
143. Masaoka T, Takaku F, Kato S, Moriyama Y, Kodera Y, Kanamaru A, et al. Recombinant human granulocyte colony-stimulating factor in allogeneic bone marrow transplantation. Exp Hematol. 1989;17: 1047-50.
144. Nemunaitis J, Singer JW, Buckner CD, Durnam D, Epstein C, Hill R, et al. Use of recombinant granulocyte-macrophage colony-stimulating factor in graft failure after bone marrow transplantation. Blood. 1990;76:245-53.
145. Champlin RE, Horowitz MM, van Bekkum DW, Camitta BM, Elfenbein GE, Gale RP, et al. Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results. Blood. 1989;73:606-13.
146. Brandwein JM, Nayar R, Baker MA, Sutton DM, Scott JG, Sutcliffe SB, et al. GM-CSF therapy for delayed engraftment after autologous bone marrow transplantation. Exp Hematol. 1991;19:191-5.
147. Blazar BR, Kersey JH, McGlave PB, Vallera DA, Lasky LC, Haake RJ, et al. In vivo administration of recombinant human granulocyte/macrophage colony-stimulating factor in acute lymphoblastic leukemia patients receiving purged autografts. Blood. 1989;73:849-57.
148. Lazarus HM, Andersen J, Chen MG, Variakojis D, Mansour EG, Oette D, et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for relapsed non-Hodgkin's lymphoma: blood and bone marrow progenitor growth studies. A phase II Eastern Cooperative Oncology Group Trial. Blood. 1991;78:830-7.
149. Brandt SJ, Peters WP, Atwater SK, Kurtzburg J, Borowitz MJ, Jones RB, et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med. 1988;318:869-76.
150. Lazarus HM, Goodnough LT, Goldwasser E, Long G, Arnold JL, Strohl KP. Serum erythropoietin levels and blood component therapy after autologous bone marrow transplantation: Implications for erythropoietin therapy in this setting. Bone Marrow Transplant. 1992;10:71-5.
151. - progenitor cells. Blood. 1991;77:1218-27.
152. + HLA-DR-bone marrow cells contain progenitor cells capable of self-renewal, multilineage differentiation, and long-term in vitro hematopoiesis. Blood Cells. 1991;17: 287-95.
153. Baum C, Weissman IL, Tsukamoto AS, Buckle AM, Peault B. Isolation of a candidate human hematopoietic stem-cell population. Proc Natl Acad Sci. 1992;89:2804-8.
154. + marrow cells in patients with breast cancer or neuroblastoma. Blood. 1991; 77:1717-22.
155. Korbling M, Dorken B, Ho AD, Pezzutto A, Hunstein W, Fliedner TM. Autologous transplantation of blood derived-hemopoietic stem cells after myeloablative therapy in a patient with Burkitt's lymphoma. Blood. 1986;67:529-32.
156. Reiffers J, Bernard P, David B, Vezon G, Sarrat A, Marit G, et al. Successful autologous transplantation with peripheral blood hemopoietic cells in a patient with acute leukemia. Exp Hematol. 1986; 14:312-5.
157. Kessinger A, Armitage JO, Landmark JD, Weisenburger DD. Reconstitution of human hematopoietic function with autologous cryopreserved circulating stem cells. Exp Hematol. 1986;14:192-6.
158. Kessinger A, Armitage JO, Landmark JD, Smith DM, Weisenburger DD. Autologous peripheral hemopoietic stem cell transplantation restores hematopoietic function following marrow ablative therapy. Blood. 1988;71:723-7.
159. Kessinger A, Vose JM, Bierman PJ, Armitage JO. High-dose therapy in autologous peripheral stem cell transplantation for patients with bone marrow metastasis and relapsed lymphoma: An alternative to bone marrow purging. Exp Hematol. 1991;19:1013-6.
160. Korbling M, Holle R, Haas R, Knauf W, Darken B, Ho AD, et al. Autologous blood stem-cell transplantation in patients with advanced Hodgkin's disease and prior radiation to the pelvic site. J Clin Oncol. 1990;8:978-85.
161. Lowry PA, Tabbara IA. Mini review. Peripheral hematopoietic stem cell transplantation: Current concepts. Exp Hematol. 1992; 20:937-42.
162. Rapoport AP, Rowe JM, Heal JM, Tanner MA, DiPersio JF. Treatment of relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma with high dose chemoradiotherapy followed by unstimulated autologous peripheral stem cell rescue. Am J Hematol. 1992;40:86-92.
163. Lobo F, Kessinger A, Landmark JD, Smith DM, Weisenburger DD, Wigton RS, et al. Addition of peripheral blood stem cells collected without mobilization techniques to transplanted autologous bone marrow did not hasten the marrow recovery following myeloablative recovery. Bone Marrow Transplant. 1991;9:389-92.
164. Kessinger A, Armitage JO, Smith DM, Landmark JD, Bierman PJ, Weisenburger DD. High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma. Blood. 1989;74:1260-5.
165. Kessinger A, Armitage JO. The evolving role of autologous peripheral stem cell transplantation following high-dose therapy for malignancies. Blood. 1991;78:211-3.
166. Juttner CA, To LB, Ho JQ, Brady PG, Dyson PG, Haylock DN, et al. Early lympho-hemopoietic recovery after autografting using peripheral blood stem cells in acute non-lymphoblastic leukemia. Trans Proc. 1988;20:40-2.
167. Gianni AM, Tarella C, Siena S, Bregni M, Boccadoro M, Lombardi F, et al. Durable and complete hematopoietic reconstitution after autografting of rhGM-CSF exposed peripheral blood progenitor cells. Bone Marrow Transplant. 1990;6:143-5.
168. Tilly H, Bastit D, Vannier JP, Moncoduit M, Piguet H. Hematological reconstitution after autologous peripheral blood transplantation. Hamatologie Und Bluttransfusion. 1987:30:560-2.
169. Elias AD, Ayash L, Andersen KC, Hunt M, Wheeler C, Schwartz G, et al. Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. Blood. 1992;79:3036-44.
170. To LB, Shepperd KM, Haylock DN, Dyson PG, Charles P, Thorp DL, et al. Single high doses of cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood. Exp Hematol. 1990;18:442-7.
171. Richman CM, Weiner RS, Yankee RA. Increasing circulating stem cells following chemotherapy in man. Blood. 1976;47:1031-9.
172. Haas R, Ho AD, Bredthauer U, Cayeux S, Egerer G, Knauf W, et al. Successful autologous transplantation of blood stem cells mobilized with recombinant human granulocyte-macrophage colony-stimulating factor. Exp Hematol. 1990;18:94-8.
173. Sheridan WP, Begley CG, Juttner CA, Szer J, To LB, Maher D, et al. Effect of peripheral-blood progenitor cells mobilized by filgrastim (G-CSF) on platelet recovery after high dose chemotherapy. Lancet. 1992;339:640-4.
174. Tarella C, Ferrero D, Bregni M, Siena S, Gallo E, Pileri A, et al. Peripheral blood expansion of early progenitor cells after high-dose cyclophosphamide and rhGM-CSF. Eur J Cancer. 1991;27:22-7.
175. Ravignani F, Siena S, Bregni M, Sciorelli G, Gianni AM, Pellegris G. Large-scale collection of circulating haematopoietic progenitors in cancer patients treated with high-dose cyclophosphamide and recombinant human GM-CSF. Eur J Cancer. 1990;26:562-4.
176. Stiff PJ, Koester AR, Weidner MK, Dvorak K, Fisher RI. Autologous bone marrow transplantation using unfractionated cells cryopreserved in dimethylsulfoxide and hydroxyethyl starch without controlled-rate freezing. Blood. 1987;70:974-8.
177. Wltherspoon RB, Storb R, Ochs HD, Fluornoy N, Kopecky KJ, Sullivan KM, et al. Recovery of antibody production in human allogeneic marrow graft recipients: influence of time posttransplantalion, the presence or absence of chronic graft-versus-host disease, and antithymocyte globulin treatment. Blood. 1981;58:360-8.
178. Lum LG, Siegneuret MC, Orcutt-Thordason N, Noges JE, Storb R. The regulation of immunoglobulin synthesis after HLA-identical bone marrow transplantation: VI. Differential rates of maturation of distinct functional groups within lymphoid subpopulations in patients after human marrow grafting. Blood. 1985;65:1422-33.
179. Lum G. The kinetics of immune reconstitution after human marrow transplantation. Blood. 1987;69:369-80.
180. Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol. 1991;28:250-9.
181. Sullivan KM, Shulman HM, Storb R, Weiden PL, Witherspoon RP, McDonald GB, et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood. 1981;57:267-76.
182. Sullivan KM, Witherspoon RP, Storb R, Weiden P, Flournoy N, Dahlberg S, et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood. 1988;72:546-54.
183. Atkinson K. Reconstitution of the hemopoietic and immune systems after marrow transplantation. Bone Marrow Transplant. 1990; 5:209-26.
184. Martin PJ, Hansen JA, Storb R, Thomas ED. Human marrow transplantation: an immunological perspective. Adv Immunol. 1987;40:379-438.
185. Livnat S, Seigneuret M, Storb R, Prentice RL. Analysis of cytotoxic effector cell function in patients with leukemia or aplastic anemia before and after marrow transplantation. J Immunol. 1980; 124:481-90.
186. Lopez C, Kirkpatrick D, Livnat S, Storb R. Natural killer cells in bone marrow transplantation. Lancet. 1980;2:1025.
187. Ault KA, Antin JH, Ginsburg D, Orkin SH, Rappeport JM, Keohan ML, et al. Phenotype of recovering lymphoid cell populations after marrow transplantation. J Exp Med. 1985;161:1483-502.
188. Antin JH, Ault KA, Rappeport JM, Smith BR. B lymphocyte reconstitution after human marrow transplantation. Leu-1 antigen defines a distinct population of B lymphocytes. J Clin Invest. 1987;80:325-32.
189. Aucouturier P, Barra A, Intrator L, Cordonnier C, Schulz D, Duarte F, et al. Long lasting IgG subclass and antibacterial polysaccharide antibody deficiency after allogeneic bone marrow transplantation. Blood. 1987;70:779-85.
190. Sheridan JF, Tutschka PJ, Sedmak DD, Copelan EA. Immunoglobulin G subclass deficiency and pneumococcal infection after allogeneic bone marrow transplantation. Blood. 1990;75:1583-6.
191. Atkinson K, Hansen JA, Storb R, Goehle S, Goldstein G, Thomas ED. T-cell subpopulations identified by monoclonal antibodies after human marrow transplantation. I. Helper-inducer and cytotoxic-suppressor subsets. Blood. 1982;59:1292-8.
192. Witherspoon RP, Goehle S, Kretschmer M, Storb R. Regulation of immunoglobulin production after human marrow grafting. The role of helper and suppressor T cells in acute graft-versus-host disease. Transplantation. 1986;41:328-35.
193. + T lymphocytes correlate with the occurrence of acute graft-versus-host disease. Blood. 1984;63:1416-23.
194. Perrson U, Myrenfors P, Ringden O, Sundberg B, Larsson P, Gunnar S, et al. T lymphocyte subpopulations in bone-marrow-transplanted patients in relation to graft-versus-host disease and cytomegalovirus-induced infection. Transplantation. 1987;43:663-8.
195. Gratama JW, Fibbe WE, Naipal AM, Slats J, Stijnen T, D'Amaro J, et al. Cytomegalovirus immunity and T lymphocytes in bone marrow donors and acute graft-versus-host disease. Bone Marrow Transplant. 1986;1:141-6.
196. Atkinson K, Storb R, Prentice RL, Weiden PL, Witherspoon RP, Sullivan K, et al. Analysis of late infections in 89 long-term survivors of bone marrow transplantation. Blood. 1979;53:720-31.
197. Meyers JD. Infections in bone marrow transplant recipients. Am J Med. 1986;81:27-38.
198. Atkinson K, Farewell V, Storb R, Tsoi MS, Sullivan KM, Witherspoon RP, et al. Analysis of late infections after human bone marrow transplantation: role of genotypic nonidentity between marrow donor and recipient and of nonspecific suppressor cells in patients with chronic graft-versus-host disease. Blood. 1982;60: 714-20.
199. Update in Adult Immunization: Recommendations of the Immunization Practices Advisory Committee. MMWR Morbid Mortal Wkly Rep. 1991;40:5-13.
200. Engelhard D, Handsher R, Naparstek E, Harden I, Strauss N, Aker M, et al. Immune response to polio vaccination in bone marrow transplant recipients. Bone Marrow Transplant. 1991;8:295-300.